AUGTYRO

This brand name is authorized in Lithuania, United States

Active ingredients

The drug AUGTYRO contains one active pharmaceutical ingredient (API):

1 Repotrectinib UNII 08O3FQ4UNP - REPOTRECTINIB

Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1, the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, TRKC, and anaplastic lymphoma kinase (ALK). Repotrectinib has demonstrated in vitro and in vivo inhibition of cell lines expressing the targeted fusion oncogenes ROS1, TRKA, TRKB, TRKC, and corresponding mutations (ROS1G2032R, ROS1D2033N, TRKAG595R, TRKBG639R, TRKCG623R). Read about Repotrectinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AUGTYRO Capsule, hard	European Medicines Agency (EU)	MPI, EU: SmPC
AUGTYRO Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX28		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX28

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1102333, 1102334, 1102335, 1102336
Country: US	FDA, National Drug Code	Identifier(s): 0003-4040, 0003-4160